Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Airbnb, Inc. (ABNB) vs Novo Nordisk A/S (NVO) Price & Performance

Airbnb, Inc.Trade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Airbnb, Inc. vs Novo Nordisk A/S — how do they compare? Airbnb, Inc. trades at $180.63 (market cap $110.76B), while Novo Nordisk A/S trades at $46.24 (market cap $207.85B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays a 3.81% dividend while Airbnb, Inc. pays none. Which is the better fit depends on your goals.

ABNBNVO
Market Cap
$110.76B$207.85B
Sector
Consumer CyclicalHealth
52-Week High
$184.98$63.98
52-Week Low
$111.54$35.29
Enterprise Value
$101.19B$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Airbnb, Inc.

ABNB trades at $180.06, down 2.51% today but remains near recent highs following strong Q2 2026 earnings that beat expectations. The stock shows bullish technical momentum with moving averages supporting upward trends, though oscillators indicate potential overbought conditions. Fundamentally, Airbnb demonstrates robust revenue growth with $12.24B in 2025 revenue and impressive 82.9% gross margins, though valuation multiples remain elevated with a P/E of 42.23. Recent news highlights the company's strategic pivot toward AI integration and expansion into hotel listings and travel services.

The outlook remains positive with analyst consensus leaning toward Buy (46.7% of ratings) and a $173.26 price target, though current price exceeds this consensus. Key opportunities include AI-driven efficiency gains and travel demand recovery, while risks involve premium valuation sensitivity and competitive pressures in the evolving travel marketplace. Institutional sentiment appears cautiously optimistic given recent earnings momentum.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Airbnb, Inc.

Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.

Read more on ABNB

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO